CRANFORD, N.J., Jan. 25, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that its Vice President of Corporate Development, Andrew Scott, will present at NobleConXV - Noble Capital Markets' Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on Monday, January 28th at 10:00am Eastern Standard Time in Studio 2.
During the conference, Mr. Scott will deliver the Company's corporate presentation and discuss business operations and updates. Citius recently signed a license agreement with MD Anderson Cancer Center to develop and commercialize a novel approach to reducing post-operative infections associated with surgical implants. The initial product called "Mino-Wrap", or CITI 101, is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander (TE) infections following breast reconstructive surgeries.
Citius Pharmaceuticals, Inc. will also be available for one-on-one meetings. To arrange a meeting with the company, please contact Mr. Andrew Scott: [email protected].
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, please visit www.citiuspharma.com.
Contact:
Andrew Scott Vice President, Corporate Development (o) 908-967-6677 [email protected]
Advertisement
During the conference, Mr. Scott will deliver the Company's corporate presentation and discuss business operations and updates. Citius recently signed a license agreement with MD Anderson Cancer Center to develop and commercialize a novel approach to reducing post-operative infections associated with surgical implants. The initial product called "Mino-Wrap", or CITI 101, is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander (TE) infections following breast reconstructive surgeries.
Advertisement
Citius Pharmaceuticals, Inc. will also be available for one-on-one meetings. To arrange a meeting with the company, please contact Mr. Andrew Scott: [email protected].
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, please visit www.citiuspharma.com.
Contact:
Andrew Scott Vice President, Corporate Development (o) 908-967-6677 [email protected]
View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-noblecon15-investor-conference-300783963.html
SOURCE Citius Pharmaceuticals, Inc.
